FDA Calls For Class-Wide REMS For LABA Asthma Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
LABA asthma drugs are the latest group of medications to be hit with a class-wide Risk Evaluation and Mitigation Strategies requirement.